ALEXZA PHARMACEUTICALS Aktie

0,28 EUR -1,7301%

Zu Ihrem Onlinebroker

kaufen verkaufen

ALEXZA PHARMACEUTICALS Aktienkurs : 23.05. ( 15 Min. verzögert)
0,284 € Letzter Kurs	-1,73% Veränderung	0,289 € Vortag	0,284 € Eröffnungskurs

Realtime:

0,28

-1,73%

mehr Informationen

Hoch/Tief		Volumen		Geldkurs	Briefkurs
0,284 - 0,284 Tag	1,24 - 0,284 52 Wochen	0 Tag	295 Ø 52 Wochen	0,0000000 0 Stücke	0,0000000 0 Stücke

ALEXZA PHARMACEUTICALS Aktien…

Wollen Sie wissen, wie es mit dieser Aktie weitergeht?
Wir informieren Sie kostenlos.

Erhalten Sie außerdem Expertenanalysen von:
Gevestor Täglich und John Gossens Daily DAX

16.05.

Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) Investor Alert: Investigation over ...

An investigation on behalf of investors in Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) shares over potential securities laws violations by certain officers and directors at Alexza Pharmaceuticals, Inc. in connection with...
11.05.

Biotech Industry Hotbed of Merger & Acquisition Speculation

Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on Pluristem Therapeutics Inc. (UTD:PSTI) and Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) . The US patent system will see a major change for the ...

10.05.

Alexza Reports 2012 First Quarter Financial Results and Provides Business Update

MOUNTAIN VIEW, Calif., May 10, 2012 /PRNewswire via COMTEX/ -- Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) today reported financial results for the fiscal quarter ended March 31, 2012 and provided a business update. Alexza...
10.05.

ACCO, ADK, ALXA, AMCX, APEI, AGO are Releasing Earnings May-10

Alexza Pharmaceuticals Inc (ALXA) is releasing earnings After Market Closes. Alexza Pharmaceuticals, Inc. is a pharmaceutical development company focused on the research, development, and commercialization of novel proprietary products for the acute...
07.05.

Alexza (NASDAQ:ALXA) New Drug Application unaccepted, AMN (NYSE:AHS) Reports ...

Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) announced on Friday its new drug application for Adasuve, a schizophrenic and bipolar disorder treatment, cannot be permitted by the US Food and Drug Admini…